Mental health and wellness company combining the practices of administering psychedelic medicine with holistic integrated psychotherapy Numinus Wellness Inc. (TSE: NUMI) (OTCMKTS: NUMIF) announced having received a regulatory approval from Health Canada to complete psychedelic-assisted therapy using psilocybin to treat a patient suffering from treatment-resistant depression.
Apart from ongoing trials, the company’s psilocybin assisted therapy will be among the first to use this regulatory mechanisms via Health Canada’s Special Access Program (SAP) which was amended at the beginning of the year to include access of psychedelic compounds on a case-by-case basis.
For one to be considered for the SAP program, he/she must have a serious of life threatening condition where conventional medicines have failed, are unsuitable r not available in Canada. Numinus affiliate medical practitioners are seeking to make additional applications for patients suffering from a range of mental health conditions in BC and Québec.
“I am proud that Numinus is working with Health Canada to help Canadians with mental health challenges in ways that were not previously available, including using psilocybin-assisted therapy through Health Canada’s SAP. The SAP recognizes a growing body of research that has consistently shown the efficacy of psychedelic-assisted psychotherapy to treat a broad range of mental health conditions that are extremely difficult to treat with conventional therapies. We hope that our first psilocybin-assisted therapy treatment is the beginning for more opportunities for Canadian patients to obtain safe access to treatment and care in the mental health sector through psychedelic medicine,” said the founder and CEO of Numinus, Payton Nyquvest.